KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
32 hedge funds and large institutions have $6.25M invested in KalVista Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 13 closing their positions.
0% more funds holding
Funds holding: 32 → 32 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
18% less capital invested
Capital invested by funds: $7.6M → $6.25M (-$1.35M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FQ
First Quadrant
Glendale,
California
|
+$171K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.1K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$33.6K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$31.8K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.26M |
| 2 |
Goldman Sachs
New York
|
-$405K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$257K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$88.2K |
| 5 |
State Street
Boston,
Massachusetts
|
-$69K |
KALV Hedge Fund Activity: Q2 2016 in Review
32 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2016, worth a combined $6.25M — down 18% from $7.6M a quarter earlier.
Fund positioning in KALV was balanced in Q2 2016: 13 funds opened new positions, 13 closed out, 4 added to existing stakes and 9 trimmed.
The largest buyer was First Quadrant, opening a new position worth an estimated $171K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.26M sold.
- 32 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $6.25M of KalVista Pharmaceuticals stock for Q2 2016, down 18% quarter-over-quarter.
- 13 funds opened new KalVista Pharmaceuticals positions in Q2 2016 and 13 closed out, a net change of 0 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2016 was First Quadrant, an estimated $171K added.
- The largest KalVista Pharmaceuticals seller in Q2 2016 was Fidelity Investments, an estimated $1.26M sold.
Based on aggregated 13F filings for Q2 2016.